Evidence map›Paper›PMID 42228296›Full record

ReviewMolecular biology reports2026

From fragments to full pictures: how long-read sequencing platforms are revolutionizing oncology research.

Ruby Dhar, Abhibroto Karmakar, Abhishesh Kumar Badal, Om Saswat Sahoo, Prasmita Paul, Isha Goel, Arnab Nayek, Karthikeyan Pethusamy, Ashikh Seethy, Subhradip Karmakar

Abstract readReview
PubMed Publisher
In one paragraph

Review in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ruby Dhar *Department of Biochemistry, All India Institute of Medical Sciences, New Delhi, India.
Abhibroto Karmakar *Department of Biochemistry, All India Institute of Medical Sciences, New Delhi, India.
Abhishesh Kumar BadalDepartment of Biochemistry, All India Institute of Medical Sciences, New Delhi, India.
Om Saswat SahooDepartment of Biochemistry, All India Institute of Medical Sciences, New Delhi, India.
Prasmita PaulDepartment of Biotechnology, National Institute of Technology, Durgapur, India.
Isha GoelDepartment of Biochemistry, All India Institute of Medical Sciences, New Delhi, India.
Arnab NayekDepartment of Biochemistry, All India Institute of Medical Sciences, New Delhi, India.
Karthikeyan PethusamyDepartment of Biochemistry, All India Institute of Medical Sciences, New Delhi, India.
Ashikh SeethyDepartment of Biochemistry, All India Institute of Medical Sciences, Guwahati, India. ashikhseethy@aiimsguwahati.ac.in.
Subhradip KarmakarDepartment of Biochemistry, All India Institute of Medical Sciences, New Delhi, India. subhradip.k@aiims.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Short-read sequencing (SRS) has been the cornerstone of cancer genomics for nearly two decades; however, its inherent limitations in read length have restricted comprehensive characterisation of complex genomic features. Long-read sequencing (LRS) represents not merely a technical increment but a conceptual shift from computational inference of genomic structure to its direct observation. It enables 3-4-fold greater sensitivity for structural variant detection, unambiguous full-length transcript characterisation, native DNA methylation profiling without bisulfite conversion, and high-resolution HLA typing at 8-digit allele resolution. In haematological malignancies, these capabilities have identified cryptic rearrangements in 10-15% of cases previously classified as normal karyotype, enabled novel fusion transcript discovery influencing treatment stratification, and supported minimal residual disease monitoring at 10

Indexed as

High-Throughput Nucleotide SequencingMedical OncologyNeoplasmsSequence Analysis, DNAComputational BiologyDNA MethylationGenomicsHematologic NeoplasmsHumansCancer genomicsEpigeneticsHematological malignanciesImmunogenomicsLong-read sequencingPrecision oncologyStructural variantsTranscriptome profiling

Identifiers

PMID42228296

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.